2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

EAU 2014 - Comparison of white-light, photodynamic diagnosis and narrow-band imaging for the detection of non-muscle invasive bladder cancer: Results from a randomized multicenter diagnostic phase-III study - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - White-light (WL) cystoscopy is the most commonly used procedure for the diagnosis of bladder cancer.

However, given the inability of standard cystoscopy to detect all tumors, narrow-band imaging (NBI) is a developing diagnostic approach for the detection of non-muscle invasive bladder cancer (NMIBC). NBI utilizes an optical filter technology to improve display of superficial capillaries and subepithelial vessels, and unlike photodynamic diagnosis (PDD) does not require administration of a sensitization agent. Dr. Doehn and colleagues presented data from a multicenter, phase-III trial of NMIBC detection using NBI, WL cystoscopy, and PDD at the 2014 EAU meeting in Stockholm.

eauTwo-hundred twenty patients with suspicious cytology, history of bladder cancer, and/or hematuria underwent WL, PDD, and NBI in a standardized fashion (the order of testing was randomized). Allocation remained concealed to clinicians, and all suspicious lesions were resected. The primary endpoint was diagnostic sensitivity, while secondary endpoints included diagnostic specificity and positive/negative predictive values. 32.7% of patients were previously diagnosed with NMIBC (mean time since first diagnosis 61.5 months). Among all patients, there was no significant difference in the sensitivity and specificity between NBI and WL cystoscopy. The median difference of detected tumors per patient between NBI and WL was 0. NBI demonstrated no evidence of superiority to standard WL cystoscopy. While two other meta-analyses have demonstrated higher sensitivity of NBI, the randomized order of diagnostic modality used could have contributed to the lack of an observed significant difference, and further studies are needed to define the role of NBI in the diagnosis of NMIBC.

Presented by Christian Doehn at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden

Urologikum Lübeck, Dept. of Urology, Lübeck, Germany

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe